GSK: new phase II study with Sanofi in Covid-19
(CercleFinance.com) - Sanofi and GSK announce the launch of a new phase II study with 720 volunteers over 18 years of age aimed at selecting the most appropriate antigen dose for the phase III evaluation of their adjuvanted Covid-19 candidate vaccine.
If the results are positive, the Phase III trial should start in the second quarter of 2021, with the vaccine available from the fourth quarter of 2021, the companies said.
Alongside this new phase II study, and given the emergence of new variants of SARS-CoV-2 worldwide and their potential impact on vaccine efficacy, Sanofi has begun research on new variants of SARS-CoV-2.
On Monday afternoon, the Sanofi share was just under water (-0.1%), while GSK was keeping afloat (+0.3%)
Copyright (c) 2021 CercleFinance.com. All rights reserved.